Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Immucell reports preliminary Q1 sales $4.1M, one est. $5.4M » 08:22
04/07/21
04/07
08:22
04/07/21
08:22
ICCC

Immucell

$9.82 /

-0.03 (-0.30%)

"We expect to report…

"We expect to report a 16%, or $791,000, decrease in total product sales to approximately $4.1 million during the quarter ended March 31, 2021 versus the same period of the prior year, during which our sales benefitted from a higher level of beginning inventory," commented Michael Brigham, President and CEO of ImmuCell. "This level of sales represents nearly 100% of our quarterly production capacity, underscoring the importance of the investment we are making to increase our annual production capacity from $16.5 million to $23 million, which is on schedule to be completed by June 30th. These capacity estimates are subject to biological yield variance, product format mix, selling price and other factors. We anticipated a decrease in sales for the quarter, as first publicly projected on February 22, 2021, and the amount of the decrease is consistent with what we projected in our Form 10-K filing on March 30, 2021. We expect that we can manage through this transitional drop in sales to end the year with positive sales growth year over year. Due to strong demand, the backlog of orders worth approximately $1.8 million as of December 31, 2020 increased to approximately $3 million as of March 31, 2021. Given that some orders were cancelled during the first quarter and additional orders may still be cancelled, the amount of the order backlog is not directly comparable from period to period, but it does provide some indication of the amount of unmet demand for our product."

ShowHide Related Items >><<
ICCC Immucell
$9.82 /

-0.03 (-0.30%)

ICCC Immucell
$9.82 /

-0.03 (-0.30%)

07/13/20 Aegis
Immucell initiated with a Buy at Aegis
ICCC Immucell
$9.82 /

-0.03 (-0.30%)

Over a quarter ago
Hot Stocks
Immucell submits technical sections to achieve FDA approval to market Re-Tain » 16:35
02/22/21
02/22
16:35
02/22/21
16:35
ICCC

Immucell

$11.87 /

-0.055 (-0.46%)

ImmuCell announced…

ImmuCell announced submission of a "critical" filing to the FDA related to Re-Tain and the company's unaudited financial results for the year ended December 31, 2020. The company recently submitted the last of five technical sections required to achieve FDA approval to market Re-Tain, the company's mastitis product under development. A response from the FDA to this Chemistry, Manufacturing and Controls Technical Section is expected during Q3 after the statutory six-month review period. If the FDA issues a Technical Section Complete Letter, the company would be able to begin initial, limited sales of Re-Tain during Q4 after the final sixty-day administrative review period. If the FDA issues a Technical Section Incomplete Letter, the company would re-submit for another six-month review after responding to the FDA inquiries leading to potential market launch during Q2 of 2022. The company said it is taking a prudent approach and planning for a mass market launch during 2022. The company reported a backlog of orders worth approximately $1.8M as of December 31, 2020 compared to no backlog as of December 31, 2019. The company projects that, during Q1, it may sell product equivalent to approximately 92% of the $4.1M that it estimates to be its current production capacity per quarter, resulting in a sales decrease during the first quarter of 2021 compared to the first quarter 2020. The company's investment to increase its annual production capacity from approximately $16.5M to approximately $23M is proceeding on budget and on time for completion during Q2. After fulfilling the backlog and meeting on-going strong demand, the company plans to build inventory during the second half of 2021 to prepare for peak season sales during Q1 of 2022 without risk of backlog.

ShowHide Related Items >><<
ICCC Immucell
$11.87 /

-0.055 (-0.46%)

07/13/20 Aegis
Immucell initiated with a Buy at Aegis
ICCC Immucell
$11.87 /

-0.055 (-0.46%)

Earnings
Immucell expects 2020 revenue approx. $15.3M, one est. $15.14M » 08:25
01/07/21
01/07
08:25
01/07/21
08:25
ICCC

Immucell

$5.98 /

-0.07 (-1.16%)

"We expect to report…

"We expect to report a 12% increase in total product sales to approximately $15.3M during the year ended December 31, 2020 versus the year ended December 31, 2019," commented Michael Brigham, President and CEO of ImmuCell. "As we gladly turn the calendar forward to 2021, we are very optimistic about the growth prospects for our business with expanded production capacity coming online. The First Defense product line has been exceedingly well received by the market, and this strong demand has temporarily outstripped our ability to manufacture enough product. During the second quarter of 2021, we expect to complete a $3.5M investment to expand our production capacity to approximately $23M annually, compared to our current theoretical annual capacity of approximately $16.5M. These estimates are subject to biological yield variance, product format mix and other factors. Due to strong demand, we accumulated a backlog of orders worth approximately $1.8M as of year-end. As our customers plan for their requirements in the coming months, we have seen a significant increase in order quantities during the fourth quarter. We are well positioned to meet that demand as our new production capacity comes online. With respect to the Re-Tain product development initiative, Mr. Brigham further commented, "We pushed our previously disclosed target of submitting the final Technical Section to the FDA by the end of 2020 out by about one month, reflecting actual production dates of the registration batches and required stability data. These submissions are generally subject to a six-month review by the FDA. As previously disclosed, we are planning for product launch during the third quarter of 2021 in the event of a first-time approval from the FDA or during the first quarter of 2022 if a second submission is required."

ShowHide Related Items >><<
ICCC Immucell
$5.98 /

-0.07 (-1.16%)

07/13/20 Aegis
Immucell initiated with a Buy at Aegis
ICCC Immucell
$5.98 /

-0.07 (-1.16%)

Earnings
Immucell sees Q3 revenue $3.7M, one est. $3.27M » 08:12
10/06/20
10/06
08:12
10/06/20
08:12
ICCC

Immucell

$5.56 /

-0.04 (-0.71%)

"As indicated by the…

"As indicated by the continued top line growth, our sales team has been able to pivot and be both safe and successful despite COVID-19's impact on how we work," commented Michael F. Brigham, President and CEO. "Over the longer nine-month and trailing twelve-month periods, our growth is being generated by Tri-Shield First Defense, which provides antibodies without vaccination so every calf receives a measured dose of Immediate Immunity against all three of the primary scour-causing pathogens, E. coli, coronavirus, and rotavirus. We reduced the backlog of orders that was worth approximately $1.4 million as of March 31, 2020 and approximately $945,000 as of June 30, 2020 to approximately $130,000 as of September 30, 2020. We are on budget to come on-line with 50% more freeze-drying capacity in just over a month, despite some COVID-19 related delays at the equipment manufacturer. We have deferred installation of the 100% increase in our liquid processing capacity into the first quarter of 2021, so that we can build up needed inventory before incurring the required transitional shut down of the impacted operations to move equipment and achieve USDA site license approvals."

ShowHide Related Items >><<
ICCC Immucell
$5.56 /

-0.04 (-0.71%)

ICCC Immucell
$5.56 /

-0.04 (-0.71%)

07/13/20 Aegis
Immucell initiated with a Buy at Aegis
Initiation
Immucell initiated with a Buy at Aegis » 10:56
07/13/20
07/13
10:56
07/13/20
10:56
ICCC

Immucell

$5.39 /

+ (+0.00%)

Aegis analyst Nathan…

Aegis analyst Nathan Weinstein initiated coverage of Immucell with a Buy rating and $14 price target.

ShowHide Related Items >><<
ICCC Immucell
$5.39 /

+ (+0.00%)

Conference/Events
Lytham Partners to hold a virtual conference » 04:55
06/25/20
06/25
04:55
06/25/20
04:55
MOGO

Mogo

$0.95 /

-0.0403 (-4.05%)

, SANW

S&W Seed

$2.21 /

-0.04 (-1.78%)

, MNKD

MannKind

$1.86 /

-0.265 (-12.47%)

, CDXC

ChromaDex

$4.46 /

-0.11 (-2.41%)

, SNWV

Sanuwave Health

$0.00 /

+ (+0.00%)

, EAST

Eastside Distilling

$1.52 /

+0.03 (+2.01%)

, AZZ

AZZ Inc.

$32.75 /

-1.44 (-4.21%)

, ICCC

Immucell

$4.43 /

-0.105 (-2.32%)

, INFU

InfuSystem

$11.81 /

-0.5 (-4.06%)

, LIQT

LiqTech

$5.41 /

-0.17 (-3.05%)

, TNP

TEN, Ltd.

$2.02 /

-0.1 (-4.72%)

Investor Growth Virtual…

Investor Growth Virtual Conference will be held on June 24-25 at 9 am. Webcast Link

ShowHide Related Items >><<
TNP TEN, Ltd.
$2.02 /

-0.1 (-4.72%)

SNWV Sanuwave Health
$0.00 /

+ (+0.00%)

SANW S&W Seed
$2.21 /

-0.04 (-1.78%)

MOGO Mogo
$0.95 /

-0.0403 (-4.05%)

MNKD MannKind
$1.86 /

-0.265 (-12.47%)

LIQT LiqTech
$5.41 /

-0.17 (-3.05%)

INFU InfuSystem
$11.81 /

-0.5 (-4.06%)

ICCC Immucell
$4.43 /

-0.105 (-2.32%)

EAST Eastside Distilling
$1.52 /

+0.03 (+2.01%)

CDXC ChromaDex
$4.46 /

-0.11 (-2.41%)

AZZ AZZ Inc.
$32.75 /

-1.44 (-4.21%)

MOGO Mogo
$0.95 /

-0.0403 (-4.05%)

06/04/20 B. Riley
Mogo price target lowered to $3 from $4 at B. Riley FBR
03/30/20 B. Riley
Mogo Finance price target lowered to $4 from $7 at B. Riley FBR
08/16/19 BMO Capital
Mogo Finance downgraded to Market Perform from Outperform at BMO Capital
08/16/19 BMO Capital
Mogo Finance downgraded to Market Perform from Outperform at BMO Capital
SANW S&W Seed
$2.21 /

-0.04 (-1.78%)

MNKD MannKind
$1.86 /

-0.265 (-12.47%)

12/24/19
Fly Intel: Top five analyst actions
12/24/19 Oppenheimer
MannKind initiated with an Outperform at Oppenheimer
10/25/19
Fly Intel: Top five analyst initiations
10/24/19 Cantor Fitzgerald
Cantor Fitzgerald starts MannKind at Overweight as Afrezza uptake gains traction
CDXC ChromaDex
$4.46 /

-0.11 (-2.41%)

10/16/19
Fly Intel: Top five analyst initiations
10/16/19
Oppenheimer bullish on ChromaDex, initiates with an Outperform
10/15/19 Oppenheimer
ChromaDex initiated with an Outperform at Oppenheimer
SNWV Sanuwave Health
$0.00 /

+ (+0.00%)

EAST Eastside Distilling
$1.52 /

+0.03 (+2.01%)

AZZ AZZ Inc.
$32.75 /

-1.44 (-4.21%)

ICCC Immucell
$4.43 /

-0.105 (-2.32%)

INFU InfuSystem
$11.81 /

-0.5 (-4.06%)

06/09/20 Lake Street
InfuSystem initiated with a Buy at Lake Street
LIQT LiqTech
$5.41 /

-0.17 (-3.05%)

01/22/20 Lake Street
LiqTech analyst increases confidence in recovery, says Lake Street
12/17/19 Lake Street
LiqTech to recover from furnace throughput challenges, says Lake Street
11/14/19 Craig-Hallum
LiqTech post-earnings pullback a buying opportunity, says Craig-Hallum
09/06/19 Stephens
LiqTech can materially ramp revenue and profits in 2020, says Stephens
TNP TEN, Ltd.
$2.02 /

-0.1 (-4.72%)

06/18/20
Fly Intel: Top five analyst downgrades
06/18/20 Stifel
TEN, Ltd. downgraded to Hold from Buy at Stifel
TNP TEN, Ltd.
$2.02 /

-0.1 (-4.72%)

SNWV Sanuwave Health
$0.00 /

+ (+0.00%)

SANW S&W Seed
$2.21 /

-0.04 (-1.78%)

MNKD MannKind
$1.86 /

-0.265 (-12.47%)

LIQT LiqTech
$5.41 /

-0.17 (-3.05%)

EAST Eastside Distilling
$1.52 /

+0.03 (+2.01%)

CDXC ChromaDex
$4.46 /

-0.11 (-2.41%)

AZZ AZZ Inc.
$32.75 /

-1.44 (-4.21%)

LIQT LiqTech
$5.41 /

-0.17 (-3.05%)

Conference/Events
Lytham Partners to hold a virtual conference » 08:46
06/24/20
06/24
08:46
06/24/20
08:46
MOGO

Mogo

$0.99 /

+0.0046 (+0.46%)

, SANW

S&W Seed

$2.25 /

+ (+0.00%)

, MNKD

MannKind

$2.13 /

-0.08 (-3.63%)

, CDXC

ChromaDex

$4.57 /

-0.02 (-0.44%)

, SNWV

Sanuwave Health

$0.00 /

+ (+0.00%)

, EAST

Eastside Distilling

$1.49 /

+0.04 (+2.76%)

, AZZ

AZZ Inc.

$34.19 /

+0.52 (+1.54%)

, ICCC

Immucell

$4.53 /

+0.03 (+0.67%)

, INFU

InfuSystem

$12.31 /

+0.56 (+4.77%)

, LIQT

LiqTech

$5.58 /

-0.15 (-2.62%)

, TNP

TEN, Ltd.

$2.12 /

-0.095 (-4.29%)

Investor Growth Virtual…

Investor Growth Virtual Conference will be held on June 24-25 at 9 am. Webcast Link

ShowHide Related Items >><<
TNP TEN, Ltd.
$2.12 /

-0.095 (-4.29%)

SNWV Sanuwave Health
$0.00 /

+ (+0.00%)

SANW S&W Seed
$2.25 /

+ (+0.00%)

MOGO Mogo
$0.99 /

+0.0046 (+0.46%)

MNKD MannKind
$2.13 /

-0.08 (-3.63%)

LIQT LiqTech
$5.58 /

-0.15 (-2.62%)

INFU InfuSystem
$12.31 /

+0.56 (+4.77%)

ICCC Immucell
$4.53 /

+0.03 (+0.67%)

EAST Eastside Distilling
$1.49 /

+0.04 (+2.76%)

CDXC ChromaDex
$4.57 /

-0.02 (-0.44%)

AZZ AZZ Inc.
$34.19 /

+0.52 (+1.54%)

MOGO Mogo
$0.99 /

+0.0046 (+0.46%)

06/04/20 B. Riley
Mogo price target lowered to $3 from $4 at B. Riley FBR
03/30/20 B. Riley
Mogo Finance price target lowered to $4 from $7 at B. Riley FBR
08/16/19 BMO Capital
Mogo Finance downgraded to Market Perform from Outperform at BMO Capital
08/16/19 BMO Capital
Mogo Finance downgraded to Market Perform from Outperform at BMO Capital
SANW S&W Seed
$2.25 /

+ (+0.00%)

MNKD MannKind
$2.13 /

-0.08 (-3.63%)

12/24/19
Fly Intel: Top five analyst actions
12/24/19 Oppenheimer
MannKind initiated with an Outperform at Oppenheimer
10/25/19
Fly Intel: Top five analyst initiations
10/24/19 Cantor Fitzgerald
Cantor Fitzgerald starts MannKind at Overweight as Afrezza uptake gains traction
CDXC ChromaDex
$4.57 /

-0.02 (-0.44%)

10/16/19
Fly Intel: Top five analyst initiations
10/16/19
Oppenheimer bullish on ChromaDex, initiates with an Outperform
10/15/19 Oppenheimer
ChromaDex initiated with an Outperform at Oppenheimer
SNWV Sanuwave Health
$0.00 /

+ (+0.00%)

EAST Eastside Distilling
$1.49 /

+0.04 (+2.76%)

AZZ AZZ Inc.
$34.19 /

+0.52 (+1.54%)

ICCC Immucell
$4.53 /

+0.03 (+0.67%)

INFU InfuSystem
$12.31 /

+0.56 (+4.77%)

06/09/20 Lake Street
InfuSystem initiated with a Buy at Lake Street
LIQT LiqTech
$5.58 /

-0.15 (-2.62%)

01/22/20 Lake Street
LiqTech analyst increases confidence in recovery, says Lake Street
12/17/19 Lake Street
LiqTech to recover from furnace throughput challenges, says Lake Street
11/14/19 Craig-Hallum
LiqTech post-earnings pullback a buying opportunity, says Craig-Hallum
09/06/19 Stephens
LiqTech can materially ramp revenue and profits in 2020, says Stephens
TNP TEN, Ltd.
$2.12 /

-0.095 (-4.29%)

06/18/20
Fly Intel: Top five analyst downgrades
06/18/20 Stifel
TEN, Ltd. downgraded to Hold from Buy at Stifel
TNP TEN, Ltd.
$2.12 /

-0.095 (-4.29%)

SNWV Sanuwave Health
$0.00 /

+ (+0.00%)

SANW S&W Seed
$2.25 /

+ (+0.00%)

MNKD MannKind
$2.13 /

-0.08 (-3.63%)

LIQT LiqTech
$5.58 /

-0.15 (-2.62%)

EAST Eastside Distilling
$1.49 /

+0.04 (+2.76%)

CDXC ChromaDex
$4.57 /

-0.02 (-0.44%)

AZZ AZZ Inc.
$34.19 /

+0.52 (+1.54%)

LIQT LiqTech
$5.58 /

-0.15 (-2.62%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.